Therapeutic efficacy of troventol in patients with occupational asthma or COPD

Abstract

Respiratory pathology takes 15 to 35 % of occupational diseases and a half of them falls to chronic obstructive pulmonary disease (COPD) and asthma. The aim of this study was to evaluate clinical efficiency and safety of troventol in workers of rubber industry and other hazardous fields and in agriculture workers suffering from asthma or COPD. The study involved 33 workers of hazardous industries of Moscow and 35 agriculture workers. Methods used included questionnaire, physical examination, spirometry, bronchodilating test, methacholine challenge test, peak flowmetry, measurements of NO in the exhaled air (NOexh) and total IgE level before and after treatment with troventol under the continuing hazardous exposure condition. The daily dose of troventol depended on the severity of the disease and ranged 80 to 240 μg. The therapy with troventol has resulted in improvement of cough from 1.6 to 1.2 score (р ≤ 0.05) and dyspnea from 1.12 to 0.8 (р ≤ 0.04). Asthma attacks ceased in 39.7 % of the workers. Number of the workers having normal Tiffeneau index increased from 36.4 to 48.5 %. Bronchial hyperreactivity reduced. NOexh became normal in 24% of the patients. The drug was generally well tolerated.